The <i>JAK2</i> 46/1 haplotype influences PD-L1 expression

G Gonzalo Carreño-Tarragona (1Hematology Department, Hospital Universitario 12 de Octubre, I+12, Centro Nacional de Investigaciones Oncológicas, Complutense University, Centro de Investigación Biomédica en Red de Oncología, Madrid, Spain) M María Tiana R Raquel Rouco A Alejandra Leivas (1Hematology Department, Hospital Universitario 12 de Octubre, I+12, Centro Nacional de Investigaciones Oncológicas, Complutense University, Centro de Investigación Biomédica en Red de Oncología, Madrid, Spain) J Jesús Victorino (4Functional Genomics Group, Centro Nacional de Investigaciones Cardiovasculares Carlos III, Madrid, Spain) R Roberto García-Vicente (4Department of Translational Hematology, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Hematological Malignancies Clinical Research Unit H12O-CNIO, Hospital 12 de Octubre - Centro Nacional de Investigaciones Oncológicas, CIBERONC, ES 28041, Madrid, Spain., Madrid, Spain) A Andrew J. Chase (1Faculty of Medicine, University of Southampton, Southampton, United Kingdom) A Andrea Maidana (2Tissue and Organ Homeostasis Program, Centro de Biología Molecular Severo Ochoa, Centro Superior de Investigaciones Científicas-Universidad Autónoma de Madrid, Madrid, Spain) W William J. Tapper (1Faculty of Medicine, University of Southampton, Southampton, United Kingdom) R Rosa Ayala (HOSPITAL 12 DE OCTUBRE, MADRID, Spain) N Nicholas C. P. Cross J Joaquín Martínez-López (Hospital Universitario 12 de Octubre, Instituto de Investigación Sanitaria Hospital 12 de Octubre, Complutense University of Madrid, Centro Nacional de Investigaciones Oncológicas, Madrid Institute of Cancer, Madrid) M Miguel Manzanares

Abstract

Abstract Although described more than a decade ago, the mechanism by which the JAK2 46/1 haplotype increases the risk of developing JAK2-mutated myeloproliferative neoplasms (MPNs) remains unexplained. Inflammation and immunity are linked to MPN development and thus could be relevant to the mechanism by which 46/1 mediates its effect. Here, we show that programmed death-1 receptor ligand (PD-L1) expression is elevated in 46/1 haplotype, both in healthy carriers and in CD34+ cells from patients with MPN. Using circular chromosome conformation capture, we observed that PD-L1 and the neighboring PD-L2 loci physically interact with JAK2 in a manner that differs between 46/1 and nonrisk haplotypes. CRISPR/Cas9 genome editing identified a region within JAK2 intron 2 that influences both JAK2 and PD-L1 expression. We suggest that increased PD-L1 expression may be relevant to the mechanism by which 46/1 leads to an increased inherited risk of developing MPN.

Article Details

Journal Blood
Volume / Issue Vol. 145, Issue 19
Published May 08, 2025
Pages 2196-2201
ISSN 0006-4971
Publisher Elsevier BV

Journal Info

Blood

Elsevier BV

ISSN: 0006-4971 Health Sciences

Authors (13)

G

Gonzalo Carreño-Tarragona

1Hematology Department, Hospital Universitario 12 de Octubre, I+12, Centro Nacional de Investigaciones Oncológicas, Complutense University, Centro de Investigación Biomédica en Red de Oncología, Madrid, Spain

M

María Tiana

R

Raquel Rouco

A

Alejandra Leivas

1Hematology Department, Hospital Universitario 12 de Octubre, I+12, Centro Nacional de Investigaciones Oncológicas, Complutense University, Centro de Investigación Biomédica en Red de Oncología, Madrid, Spain

J

Jesús Victorino

4Functional Genomics Group, Centro Nacional de Investigaciones Cardiovasculares Carlos III, Madrid, Spain

R

Roberto García-Vicente

4Department of Translational Hematology, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Hematological Malignancies Clinical Research Unit H12O-CNIO, Hospital 12 de Octubre - Centro Nacional de Investigaciones Oncológicas, CIBERONC, ES 28041, Madrid, Spain., Madrid, Spain

A

Andrew J. Chase

1Faculty of Medicine, University of Southampton, Southampton, United Kingdom

A

Andrea Maidana

2Tissue and Organ Homeostasis Program, Centro de Biología Molecular Severo Ochoa, Centro Superior de Investigaciones Científicas-Universidad Autónoma de Madrid, Madrid, Spain

W

William J. Tapper

1Faculty of Medicine, University of Southampton, Southampton, United Kingdom

R

Rosa Ayala

HOSPITAL 12 DE OCTUBRE, MADRID, Spain

N

Nicholas C. P. Cross

J

Joaquín Martínez-López

Hospital Universitario 12 de Octubre, Instituto de Investigación Sanitaria Hospital 12 de Octubre, Complutense University of Madrid, Centro Nacional de Investigaciones Oncológicas, Madrid Institute of Cancer, Madrid

M

Miguel Manzanares